HEALTHCARE REALTY TRUST INC

Form 10-O November 02, 2016 **Table of Contents**

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF $^{\rm X}$ 1934

For the quarterly period ended: September 30, 2016

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF $^{\rm o}$ 1934

For the transition period from to

Commission File Number: 001-11852

HEALTHCARE REALTY TRUST INCORPORATED

(Exact name of Registrant as specified in its charter)

Maryland

62 - 1507028

(State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.)

3310 West End Avenue

Suite 700

Nashville, Tennessee 37203

(Address of principal executive offices)

(615) 269-8175

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer x Accelerated filer o Non-accelerated filer o

Smaller reporting company o

(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of October 28, 2016, the Registrant had 115,878,537 shares of Common Stock outstanding.

Table of Contents

HEALTHCARE REALTY TRUST INCORPORATED FORM 10-Q

September 30, 2016

TABLE OF CONTENTS

		Page
Part I—F	<u>'inancial Informati</u> on	
Item 1.	Financial Statements	<u>1</u>
	Condensed Consolidated Balance Sheets	<u>1</u>
	Condensed Consolidated Statements of Income	<u>1</u> <u>2</u>
	Condensed Consolidated Statements of Comprehensive Income	<u>3</u>
	Condensed Consolidated Statements of Cash Flows	
	Notes to the Condensed Consolidated Financial Statements	<u>4</u> <u>5</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>17</u>
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	<u> 29</u>
<u>Item 4.</u>	Controls and Procedures	<u>29</u>
Part II—(Other Information	
Item 1.	Legal Proceedings	<u>30</u>
Item 1A.	Risk Factors	<u>30</u>
Item 6.	<u>Exhibits</u>	<u>31</u>
<u>Signature</u>		<u>32</u>

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements
Healthcare Realty Trust Incorporated
Condensed Consolidated Balance Sheets
(Amounts in thousands, except per share data)

	(Unaudited)			
	September 30	December 31,		
	2016	2015		
ASSETS				
Real estate properties:				
Land	\$ 206,647	\$ 198,585		
Buildings, improvements and lease intangibles	3,322,293	3,135,893		
Personal property	10,124	9,954		
Construction in progress	45,734	19,024		
Land held for development	17,438	17,452		
	3,602,236	3,380,908		
Less accumulated depreciation and amortization	(835,276)	(761,926)		
Total real estate properties, net	2,766,960	2,618,982		
Cash and cash equivalents	12,649	4,102		
Assets held for sale and discontinued operations, net	14,732	724		
Other assets, net	197,380	186,416		
Total assets	\$2,991,721	\$2,810,224		
LIABILITIES AND STOCKHOLDERS' EQUITY				
Liabilities:				
Notes and bonds payable	\$1,239,062	\$1,424,992		
Accounts payable and accrued liabilities	71,052	75,489		
Liabilities of properties held for sale and discontinued operations	572	33		
Other liabilities	46,441	66,963		
Total liabilities	1,357,127	1,567,477		
Commitments and contingencies				
Stockholders' equity:				
Preferred stock, \$.01 par value per share; 50,000 shares authorized; none issued and				
outstanding	_	_		
Common stock, \$.01 par value per share; 150,000 shares authorized; 115,878 and				
101,517 shares issued and outstanding at September 30, 2016 and December 31, 2015,	1,160	1,015		
respectively				
Additional paid-in capital	2,916,816	2,461,376		
Accumulated other comprehensive loss	(1,443)	(1,569)		
Cumulative net income attributable to common stockholders	942,819	909,685		
Cumulative dividends	(2,224,758)	(2,127,760)		
Total stockholders' equity		1,242,747		
Total liabilities and stockholders' equity	\$2,991,721	\$2,810,224		
- ·				

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated Condensed Consolidated Statements of Income For the Three and Nine Months Ended September 30, 2016 and 2015 (Amounts in thousands, except per share data) (Unaudited)

	Three Mor	nths Ended	Nine Months Ended			
	September	30,	September	30,		
	2016	2015	2016	2015		
REVENUES						
Rental income	\$102,534	\$95,383	\$302,746	\$285,867		
Mortgage interest		29	_	91		
Other operating	1,125	1,313	3,576	3,931		
	103,659	96,725	306,322	289,889		
EXPENSES						
Property operating	37,504	35,247	109,173	103,437		
General and administrative	8,724	6,258	27,098	19,709		
Depreciation	29,273	26,571	85,494	79,511		
Amortization	2,712	2,386	8,174	7,528		
Bad debts, net of recoveries	(47	(21)	(8)	(202)		
	78,166	70,441	229,931	209,983		
OTHER INCOME (EXPENSE)						
Gain on sales of real estate assets		5,915	1	47,464		
Interest expense	(13,759)	(15,113)	(43,512)	(50,649)		
Loss on extinguishment of debt				(27,998)		
Pension termination			(4)	(5,260)		
Impairment of real estate assets		(310)	_	(3,638)		
Impairment of internally-developed software			_	(654)		
Interest and other income, net	123	72	301	311		
	(13,636)	(9,436)	(43,214)	(40,424)		
INCOME FROM CONTINUING OPERATIONS	11,857	16,848	33,177	39,482		
DISCONTINUED OPERATIONS						
Income (loss) from discontinued operations	(23	61	(50)	725		
Gain on sales of real estate properties		10,571	7	10,571		
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	(23	10,632	(43)	11,296		
NET INCOME	\$11,834	\$27,480	\$33,134	\$50,778		
BASIC EARNINGS PER COMMON SHARE:						
Income from continuing operations	\$0.10	\$0.17	\$0.31	\$0.40		
Discontinued operations	0.00	0.11	0.00	0.11		
Net income	\$0.10	\$0.28	\$0.31	\$0.51		
DILUTED EARNINGS PER COMMON SHARE:						
Income from continuing operations	\$0.10	\$0.17	\$0.31	\$0.40		
Discontinued operations	0.00	0.10	0.00	0.11		
Net income	\$0.10	\$0.27	\$0.31	\$0.51		
WEIGHTED AVERAGE COMMON SHARES	114,152	99,337	106,552	98,994		
OUTSTANDING—BASIC	117,134	11,331	100,332	70,77 4		
WEIGHTED AVERAGE COMMON SHARES	115,052	99,997	107,366	99,694		
OUTSTANDING—DILUTED	•					
	\$0.30	\$0.30	\$0.90	\$0.90		

DIVIDENDS DECLARED, PER COMMON SHARE, DURING THE PERIOD

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated Condensed Consolidated Statements of Comprehensive Income For the Three and Nine Months Ended September 30, 2016 and 2015 (Dollars in thousands) (Unaudited)

	Three M	onths	Nine Months		
	Ended S	eptember	Ended Septembe		
	30,	30,			
	2016	2015	2016	2015	
NET INCOME	\$11,834	\$27,480	\$33,134	\$50,778	
Other comprehensive income (loss):					
Defined benefit plans:					
Reclassification adjustment for losses included in net income (Pension				2,519	
termination)			_	2,317	
Forward starting interest rate swaps:					
Unrecognized loss on cash flow hedges			_	(1,684)	
Reclassification adjustment for losses included in net income (Interest expense)	42	42	126	73	
Total other comprehensive income	42	42	126	908	
COMPREHENSIVE INCOME	\$11,876	\$27,522	\$33,260	\$51,686	

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated Condensed Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2016 and 2015 (Dollars in thousands) (Unaudited)

(Unaudica)			
	Nine Mor Ended Se 30,		
	2016	2015	
OPERATING ACTIVITIES			
Net income	\$33,134	\$50,778	}
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	96,145	90,000	
Stock-based compensation	5,649	4,558	
Straight-line rent receivable	(5,446)	(7,671)
Straight-line rent liability	(93)	583	
Gain on sales of real estate assets	(8)	(58,092)
Loss on extinguishment of debt		27,998	
Impairment of real estate assets		3,638	
Pension termination	_	5,260	
Impairment of internally-developed software	_	654	
Provision for bad debts, net	(8)	(203)
Changes in operating assets and liabilities:			
Other assets	(1,436)	(2,502)
Accounts payable and accrued liabilities	(3,889)	(2,285)
Other liabilities	(21,628)	594	
Net cash provided by operating activities	102,420	113,310)
INVESTING ACTIVITIES			
Acquisitions of real estate	(162,702)	(70,043)
Development of real estate	(28,508)	(10,165)
Additional long-lived assets	(49,794)	(35,709)
Proceeds from sales of real estate	_	134,432	,
Proceeds from mortgages and notes receivable repayments	14	1,914	
Net cash (used in) provided by investing activities	(240,990)	20,429	
FINANCING ACTIVITIES			
Net (repayments) borrowings on unsecured credit facility	(125,000)	57,000	
Repayment on term loan	(50,000)		
Borrowings of mortgage note payable	11,500	249,793	
Repayments on notes and bonds payable	(36,786)	(49,632)
Redemption of notes and bonds payable		(333,222	2)
Dividends paid	(96,998)	(90,078)
Net proceeds from issuance of common stock	450,304	41,757	
Common stock redemptions	(1,282)	(271)
Settlement of swaps		(1,684)
Debt issuance and assumption costs	(4,621)	(2,424)
Net cash provided by (used in) financing activities	147,117	(128,76)	1)
Increase in cash and cash equivalents	8,547	4,978	
Cash and cash equivalents, beginning of period	4,102	3,519	
Cash and cash equivalents, end of period	\$12,649	\$8,497	

Supplemental Cash Flow Information:

Interest paid	\$43,879	\$55,995
Invoices accrued for construction, tenant improvements and other capitalized costs	\$10,014	\$8,924
Mortgage notes payable assumed upon acquisition (adjusted to fair value)	\$13,951	\$19,431
Capitalized interest	\$828	\$113

The accompanying notes, together with the Notes to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, are an integral part of these financial statements.

Table of Contents

Healthcare Realty Trust Incorporated

Notes to the Condensed Consolidated Financial Statements September 30, 2016 (Unaudited)

Note 1. Summary of Significant Accounting Policies

Business Overview

Healthcare Realty Trust Incorporated (the "Company") is a real estate investment trust ("REIT") that integrates owning, managing, financing and developing income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of September 30, 2016, the Company had investments of approximately \$3.5 billion in 202 real estate properties located in 29 states totaling approximately 14.5 million square feet. The Company provided leasing and property management services to approximately 10.1 million square feet nationwide.

Basis of Presentation

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. However, except as disclosed herein, management believes there has been no material change in the information disclosed in the Notes to the Consolidated Financial Statements included in the Annual Report on Form 10-K for the year ended December 31, 2015. All material intercompany transactions and balances have been eliminated in consolidation.

This interim financial information should be read in conjunction with the financial statements included in this report and in the Company's Annual Report on Form 10-K for the year ended December 31, 2015. Management believes that all adjustments of a normal, recurring nature considered necessary for a fair presentation have been included. In addition, the interim financial information does not necessarily represent or indicate what the operating results will be for the year ending December 31, 2016 for many reasons including, but not limited to, acquisitions, dispositions, capital financing transactions, changes in interest rates and the effects of other trends, risks and uncertainties.

Use of Estimates in the Condensed Consolidated Financial Statements

Preparation of the Condensed Consolidated Financial Statements in accordance with GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.

New Accounting Pronouncements

Accounting Standards Update No. 2014-09 and No. 2015-14

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, "Revenue from Contracts with Customers," a comprehensive new revenue recognition standard that supersedes most existing revenue recognition guidance, including sales of real estate. This standard's core principle is that a company will recognize revenue when it transfers goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. However, leasing contracts, representing the major source of the Company's revenues, are not within the scope of the new standard and will continue to be accounted for under other standards.

In August 2015, the FASB issued ASU No. 2015-14, "Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date." This standard is effective for the Company for annual and interim periods beginning after December 15, 2017 with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that year. The Company is currently evaluating the impact from the adoption of

this new standard on the Consolidated Financial Statements and related notes.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Accounting Standards Update No. 2015-03

In April 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs." This standard required debt issuance costs to be reported in the balance sheet as a direct reduction from the face amount of the note to which it is directly related. In August 2015, the FASB issued ASU No. 2015-15, "Presentation and Subsequent Measurement of

Debt Issuance Costs Associated with Line-of-Credit Arrangements," which allowed entities to defer and present debt issuance costs related to line-of-credit arrangements as assets regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted this standard as of January 1, 2016. As a result of the adoption, all deferred financing costs, excluding costs related to the unsecured revolving credit facility, were reclassified to Notes and bonds payable. Unsecured revolving credit facility costs remain classified as an asset and will continue to be amortized over the remaining term.

The guidance requires retrospective adoption for all prior periods presented. The following table represents the previously reported balances and reclassified balances for the impacted line items of the Consolidated Balance Sheets as of December 31, 2015:

(in thousands)	December 3 As Previously	31, 2015 As		
(in thousands)	Reported	Reclassified		
Other assets, net	\$192,918	\$ 186,416		
Total assets	\$2,816,726	\$2,810,224		
Notes and bonds payable	\$1,431,494	\$1,424,992		
Total liabilities	\$1,573,979	\$1,567,477		
Total liabilities and stockholders' equity	\$2,816,726	\$2,810,224		

Accounting Standards Update No. 2015-16

In September 2015, the FASB issued ASU No. 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments." This standard requires adjustments to provisional amounts that are identified during the measurement period after a business combination to be recognized in the reporting period in which the adjustment amounts are determined. The adjustments recognized in the current period include the effects on earnings of changes in depreciation, amortization, or other income effects as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The Company adopted this standard effective as of January 1, 2016. The adoption of this standard had no impact on the Company's consolidated financial position or cash flows.

Accounting Standards Update No. 2016-02

In February 2016, the FASB issued ASU No. 2016-02, "Leases." For lessees, the new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For lessors, the new standard requires a lessor to classify leases as either sales-type, finance or operating. A lease will be treated as a sale if it transfers all of the risks and rewards, as well as control of the underlying asset, to the lessee. If risks and rewards are conveyed without the transfer of control, the lease is treated as financing. If the lessor doesn't convey risks and rewards or control, an operating lease results.

The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessors for sales-type, direct financing,

and operating existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact from the adoption of this new standard on the Consolidated Financial Statements and related notes.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Accounting Standards Update No. 2016-09

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation; Improvements to Employee Share-Based Payment Accounting." This update was issued as part of the simplification initiative. The areas of simplification relevant to the Company include the following:

Forfeitures - an entity can make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures when they occur.

Minimum statutory tax withholding requirements - the threshold to qualify for equity classification permits withholding up to the maximum statutory tax rates in the applicable jurisdiction.

Classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax-withholding purposes - cash paid by an employer when directly withholding shares for tax-withholding purposes should be classified as a financing activity.

This standard is effective for the Company for annual and interim periods beginning on January 1, 2017 with early adoption permitted. The Company adopted this standard effective January 1, 2016. There was no impact to the Company's Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Accounting Standards Update No. 2016-15

In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows; Classification of Certain Cash Receipts and Cash Payments." This update clarifies whether the following items should be classified as operating, investing or financing in the statement of cash flows: (i) debt prepayments and extinguishment costs, (ii) settlement of zero-coupon debt, (iii) settlement of contingent consideration, (iv) insurance proceeds, (v) settlement of corporate-owned life insurance and bank-owned life insurance policies, (vi) distributions from equity method investees, (vii) beneficial interest in securitization transactions and (viii) receipts and payments with aspects of more than one class of cash flows.

This standard is effective for the Company for annual and interim periods beginning on January 1, 2018 on a retrospective transition method to each period presented. The Company does not expect an impact to the Company's Condensed Consolidated Financial Statements resulting from the adoption of this standard.

Note 2. Real Estate Investments

2016 Acquisitions

First Quarter

In March 2016, the Company acquired a 69,712 square foot medical office building in Seattle, Washington for a purchase price of \$38.3 million, including purchase price credits of \$0.6 million and cash consideration of \$37.7 million. In addition, the Company expensed \$1.6 million of acquisition costs related to seller credits for loan prepayment, brokerage commission and excise taxes. The property is adjacent to UW Medicine's Northwest Hospital and Medical Center campus, a 281-bed general medical and surgical hospital. Upon acquisition, the building was 100% leased.

Second Ouarter

In April 2016, the Company acquired a 46,637 square foot medical office building in Seattle, Washington for a purchase price of \$21.6 million. The transaction included purchase price credits of \$1.5 million, cash consideration of \$18.8 million, and capital obligations of \$1.3 million. The property is located on UW Medicine's Valley Medical Center campus, a 321-bed general medical and surgical hospital. Upon acquisition, the building was 100% leased. This transaction was accounted for as an asset acquisition as the property was seller occupied.

In May 2016, the Company acquired a 63,012 square foot medical office building in Los Angeles, California for a purchase price of \$20.0 million, including purchase price credits of \$0.3 million, cash consideration of \$6.5 million, and the assumption of debt of \$13.2 million (excluding a \$0.8 million fair value premium recorded at acquisition). The

mortgage note payable assumed by the Company bears a contractual interest rate of 4.77% and matures on January 6, 2024. The property is located on HCA's West Hills Hospital and Medical Center campus, a 225-bed general medical and surgical hospital. Upon acquisition, the property was 80% leased.

Third Quarter

In September 2016, the Company acquired an 87,462 square foot medical office building in Seattle, Washington for a purchase price of \$53.1 million, including purchase price credits of \$0.1 million and cash consideration of \$53.0 million. The property is located on UW Medicine's Valley Medical Center campus, a 321-bed general medical and surgical hospital. Upon acquisition, the building was 100% leased.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Also in September 2016, the Company acquired a 103,783 square foot medical office building located in suburban Washington, D.C. for a purchase price of \$45.2 million, including purchase price credits of \$0.1 million and cash consideration of \$45.1 million. The property is located on Inova Health System's Loudoun Hospital campus, a 183-bed acute care hospital. Upon acquisition, the building was 100% leased. A director of the Company serves as the President and Chief Executive Officer of the Inova Health System, a more than 1,700-bed hospital system. As part of this transaction, the Company assumed a ground lease and tenant leases with Loudoun Hospital Center, an affiliate of Inova Health System.

The following table details the Company's acquisitions for the nine months ended September 30, 2016:

(Dollars in millions)	Date Acquired	Purchase Price	Purchase Price Credits	Notes Payable	Cash Consideration	Real Estate	Other (4)	Square Footage
Real estate acquisition	ons							
Washington	3/31/16	\$ 38.3	\$ (0.6)	\$ <i>—</i>	\$ 37.7	\$37.7	\$—	69,712
Washington	4/29/16	21.6	(2.8)	_	18.8	20.1	(1.3)	46,637
California	5/13/16	20.0	(0.3)	(13.2)	6.5	20.4	(0.7)	63,012
Washington	9/12/16	53.1	(0.1)	_	53.0	54.6	(1.6)	87,462
Washington, D.C.	9/26/16	45.2	(0.1)	_	45.1	43.7	1.4	103,783
		\$ 178.2	\$ (3.9)	\$ (13.2)	\$ 161.1	\$176.5	\$(2.2)	370,606

⁽¹⁾ Includes tenant improvement and capital expenditure obligations as well as other assets acquired and liabilities assumed upon acquisition.

Subsequent Acquisitions

On October 11, 2016, the Company acquired an 82,763 square foot medical office building and a 30,868 square foot medical office building in Baltimore, Maryland for a total purchase price of \$36.3 million, including purchase price adjustments of \$0.1 million and cash consideration of \$36.4 million. The properties are located on University of Maryland's Upper Chesapeake Health Medical Center campus, a 181-bed acute care hospital. Upon acquisition, the buildings were 92% leased.

On October 17, 2016, the Company acquired a 29,753 square foot medical office building in Seattle, Washington for a purchase price and cash consideration of \$9.8 million. The property is located on Providence Health's Swedish Edmonds campus, a 217-bed acute care hospital. Upon acquisition, the building was 96% leased.

Subsequent Dispositions

On October 14, 2016, the Company disposed of an on-campus, 70,908 square foot medical office building located in Kansas City, Kansas following the ground lessor's exercise of its purchase option. The Company's net investment in the building was \$7.2 million. The sales price and cash proceeds were approximately \$15.1 million. The Company expects to recognize a \$7.6 million gain on the disposal, net of straight-line rent receivables and other assets. This property was classified as held for sale as of September 30, 2016.

The mortgage note payable assumed in the acquisition does not reflect the fair value adjustments totaling \$0.8 million recorded by the Company upon acquisition (included in Other).

⁽³⁾ Cash consideration excludes prorations of revenue and expense due to/from seller at the time of the acquisition.

⁽⁴⁾ Includes assets acquired, liabilities assumed, intangibles recognized at acquisition and fair value adjustments on debt assumed.

On October 28, 2016, the Company disposed of an off-campus, 45,274 square foot medical office building located in Nashville, Tennessee, in which the Company had a net investment of approximately \$6.3 million. The sales price of the building was approximately \$8.8 million, including net proceeds of approximately \$8.6 million and closing costs of approximately \$0.2 million. The Company expects to recognize a \$2.1 million gain on the disposition, net of straight-line rent receivables and other assets. The Company also repaid the related mortgage note payable bearing interest at a rate of 7.63% with outstanding principal of \$0.1 million. This property was classified as held for sale as of September 30, 2016.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Assets Held for Sale

At September 30, 2016 and December 31, 2015, the Company had three and one properties, respectively, classified as held for sale. During the third quarter of 2016, the Company reclassified two properties to held for sale that are summarized below:

an on-campus, 70,908 square foot medical office building located in Kansas City, Kansas reclassified to held for sale in connection with the exercise of the ground lessor's purchase option. The property was sold in the fourth quarter and the Company expects to recognize a \$7.6 million gain on the disposition; and

an off-campus, 45,274 square foot medical office building located in Nashville, Tennessee reclassified to held for sale in connection with management's decision to sell the property. The property was sold in the fourth quarter and the Company expects to recognize a \$2.1 million gain on the disposition.

The table below reflects the assets and liabilities of the properties classified as held for sale and discontinued operations as of September 30, 2016 and December 31, 2015:

(Dollars in thousands)	September 30, 2016	December 31, 2015
Balance Sheet data:		
Land	\$ 2,161	\$ 422
Buildings, improvements and lease intangibles	27,198	1,350
Personal property	5	_
	29,364	1,772
Accumulated depreciation	(15,086)	(1,070)
Real estate assets held for sale, net	14,278	702
Other assets, net (including receivables)	454	22
Assets held for sale and discontinued operations, net	\$ 14,732	\$ 724
Notes and bonds payable	\$ 114	\$ —
Accounts payable and accrued liabilities	298	28
Other liabilities	160	5
Liabilities of properties held for sale and discontinued operations	\$ 572	\$ 33

Discontinued Operations

The following table represents the results of operations of the properties included in discontinued operations on the Company's Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2016 and 2015.

	Three Months Ended		Nine 1				
			Ended				
	September 30,			September 30,			
(Dollars in thousands)	2016	2015	2016	2015			
Statements of Income data:							
Revenues							
Rental income	\$ —	\$62	\$ —	\$752			
		62	_	752			
Expenses							
Property operating	23	2	50	48			
Bad debts, net of recoveries		(1) —	(1)		
	23	1	50	47			

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Note 3. Notes and Bonds Payable

The table below details the Company's notes and bonds payable.

	Maturity	Balance as	of	Rate as of	
(Dollars in thousands)	Dates	September December 30, 2016 31, 2015		September 30, 2016	
Unsecured Credit Facility	7/20	\$81,000	\$206,000	1.53	%
Unsecured Term Loan Facility, net of issuance costs	2/19	149,432	199,257	1.72	%
Senior Notes due 2021, net of discount and issuance costs	1/21	396,980	396,489	5.97	%
Senior Notes due 2023, net of discount and issuance costs	4/23	247,196	246,897	3.95	%
Senior Notes due 2025, net of discount and issuance costs	5/25	247,764	247,602	4.08	%
Mortgage notes payable, net of discounts and issuance costs and including premiums	5/17-5/40	116,690	128,747	5.14	%

2016 Activity

First Quarter

On January 5, 2016, the Company obtained a mortgage note payable of \$11.5 million bearing interest at a rate of 3.60% that encumbers a 90,607 square foot medical office building and garage located in California. The Company repaid in full the previous mortgage note payable bearing an interest rate of 5.49% with outstanding principal of \$11.4 million on December 31, 2015.

\$1,239,062 \$1,424,992

On February 11, 2016, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.86% with outstanding principal of \$10.2 million. The mortgage note encumbered a 90,633 square foot medical office building located in North Carolina.

Second Ouarter

On April 29, 2016, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.99% with outstanding principal of \$7.3 million. The mortgage note encumbered a 42,957 square foot medical office building located in Virginia.

On May 13, 2016, upon acquisition of a 63,012 square foot medical office property in Los Angeles, California, the Company assumed a \$13.2 million mortgage note payable (excluding a fair value premium adjustment of \$0.8 million). The mortgage note payable has a contractual interest rate of 4.77% (effective rate of 4.13%).

Third Quarter

With proceeds of the equity offering that the Company completed on July 5, 2016, the Company repaid \$50.0 million on its unsecured term loan facility due 2019 (the "Unsecured Term Loan") leaving an outstanding balance of \$150.0 million with a weighted average interest rate of approximately 1.6%.

On July 29, 2016, the Company entered into an amendment to its unsecured credit facility due 2017 (the "Unsecured Credit Facility") that extended the maturity date from April 2017 to July 2020, reduced the spread over LIBOR that the Company pays for borrowing, and revised financial covenants to provide the Company with increased flexibility. Amounts outstanding under the Unsecured Credit Facility bear interest at LIBOR plus an applicable margin rate. The margin rate, which depends on the Company's credit ratings, ranges from 0.83% to 1.55% (currently at 1.00%). In addition, the Company pays a facility fee per annum on the aggregate amount of commitments ranging from 0.13% to 0.30% (currently at 0.20%). In connection with the amendment, the Company paid upfront fees to the lenders and other costs of approximately \$4.4 million, which will be amortized over the term of the Unsecured Credit Facility. As of September 30, 2016, the Company had an outstanding principal balance of \$81.0 million under the Unsecured Credit Facility and had a remaining borrowing capacity of \$619.0 million.

On July 29, 2016, the Company also entered into an amendment to the Unsecured Term Loan. This amendment was for the purpose of conforming the financial covenants in the Unsecured Term Loan to those in the amendment to the

Unsecured Credit Facility. The amendment did not impact the maturity date or cost of borrowing under the Unsecured Term Loan.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

On September 1, 2016, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.01% with outstanding principal of \$15.7 million. The mortgage note encumbered a 70,623 square foot medical office building located in the state of Washington.

Note 4. Derivative Financial Instruments

Risk Management Objective of Using Derivatives

In addition to operational risks which arise in the normal course of business, the Company is exposed to economic risks such as interest rate, liquidity and credit risk. In certain situations, the Company may enter into derivative financial instruments such as interest rate swap and interest rate cap agreements to manage interest rate risk exposure arising from variable rate debt transactions that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates. The Company's objective in using interest rate derivatives is to manage its exposure to interest rate movements on its variable rate debt.

Cash Flow Hedges of Interest Rate Risk

Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without changing the underlying notional amount.

As of September 30, 2016, the Company did not have any outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk.

The effective portion of changes in the fair value of derivatives designated as, and that qualify as, cash flow hedges is recorded in accumulated other comprehensive income or loss ("OCI") and is reclassified into earnings as interest expense in the period that the hedged forecasted transaction affects earnings. The effective portion of the Company's interest rate swaps that was recorded in the accompanying Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2016 and 2015 respectively, was as follows:

	1.1	пее				
	M	ontl	ıs	Nine M	onths	
(Dollars in thousands)	Eı	ided	l	Ended		
	Se	pter	mber	Septem	ber 30,	
	30	١,				
	20	16	2015	2016	2015	
Amount of loss recognized in OCI on derivative (effective portion)	\$-	_	\$	\$	\$(1,684	F)
Amount of loss reclassified from accumulated OCI into Interest Expense (effection)	ctive \$(42)	\$(42)	\$(126)	\$(73)
Amount of gain (loss) recognized in income on derivative (ineffective portion amount excluded from effectiveness testing)	and \$-	_	\$—	\$—	\$—	

The Company estimates that an additional \$0.2 million will be reclassified from accumulated other comprehensive loss as an increase to interest expense over the next 12 months.

Note 5. Commitments and Contingencies

Legal Proceedings

The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

Redevelopment Activity

The Company is in the process of redeveloping two medical office buildings in Tennessee, including a 70,000 square foot expansion. The Company spent approximately \$45.8 million on the redevelopment of these properties through September 30, 2016, including the acquisition of a land parcel for \$4.3 million on which the Company constructed a parking garage. The total redevelopment budget for these properties is \$51.8 million. The garage and the core and shell of the expansion were completed in October 2016. The Company expects tenants to begin taking occupancy of the expansion space in the first quarter of 2017.

Development Activity

The Company is developing a 98,000 square foot medical office building in Colorado. The total development budget is \$26.5 million, of which \$7.4 million has been spent as of September 30, 2016. Construction is expected to be completed in the second quarter of 2017.

Table of Contents

Completed Developments

The Company completed the redevelopment of a medical office building in Alabama, which included the construction of a parking garage. Construction of the garage was completed in the fourth quarter of 2015. The total redevelopment budget is \$15.4 million, of which \$14.8 million has been spent as of September 30, 2016. The remaining \$0.6 million budgeted for the project is primarily related to a tenant improvement allowance that is expected to be funded in 2016. The Company developed a 12,900 square foot retail center in Texas, which is adjacent to two of the Company's existing medical office buildings associated with Baylor Scott & White Health. Construction was completed on April 15, 2016. The total development budget is \$5.6 million, of which \$5.1 million has been spent as of September 30, 2016. These amounts include \$1.5 million used by the Company to purchase land in 2006 and previously recorded as land held for development. The project is 100% leased and the remaining \$0.5 million budgeted for the project is related to tenant build-out that is expected to be completed by the end of 2016.

The table below details the Company's construction activity as of September 30, 2016. The information included in the table below represents management's estimates and expectations at September 30, 2016, which are subject to change. The Company's disclosures regarding certain projections or estimates of completion dates may not reflect actual results.

			Balance at September 30,						
			2016						
(Dollars in thousands)	Number of Properties	Estimated Completion Date	in Progress Balance	Amounts		Estimated Remaining Fundings	Total	Approximate Square t Feet	
Construction Ac	tivity								
Nashville, TN	2	Q1 2017	\$38,346	\$ 7,429	\$45,775	\$ 6,025	\$ 51,800	294,000	
Denver, CO	1	Q2 2017	7,388	_	7,388	19,112	26,500	98,000	
Total			\$45,734	\$ 7,429	\$53,163	\$ 25,137	\$ 78,300	392,000	

Note 6. Stockholders' Equity

The following table provides a reconciliation of total stockholders' equity for the nine months ended September 30, 2016:

(Dollars in thousands, except per shar data)	e Commor Stock	Additional Paid-In Capital	Accumulated Other Comprehens Loss	Cumulative I Net Income ivAttributable to Common Stockholder		Total Stockholders' Equity
Balance at December 31, 2015	\$ 1,015	\$2,461,376	\$ (1,569	\$ 909,685	\$(2,127,760)	\$1,242,747
Issuance of common stock	142	450,204				450,346
Common stock redemptions		(410)				(410)
Stock-based compensation	3	5,646				5,649
Net income		_		33,134		33,134
Reclassification of loss on forward starting interest rate swaps	_		126		_	126
Dividends to common stockholders (\$0.90 per share)	_	_	_	_	(96,998)	(96,998)
Balance at September 30, 2016	\$ 1,160	\$2,916,816	\$ (1,443	\$ 942,819	\$(2,224,758)	\$1,634,594

Common Stock

The following table provides a reconciliation of the beginning and ending shares of common stock outstanding for the nine months ended September 30, 2016 and the year ended December 31, 2015:

September 30, December 31,

2016	2015
2010	2013

 Balance, beginning of period
 101,517,009
 98,828,098

 Issuance of common stock
 14,054,146
 2,493,171

 Nonvested share-based awards, net of withheld shares
 307,138
 195,740

 Balance, end of period
 115,878,293
 101,517,009

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Equity Offering

On July 5, 2016, the Company issued 9,200,000 shares of common stock, par value \$0.01 per share, at \$33.13 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after offering expenses, were approximately \$304.6 million. A portion of the proceeds were used to repay indebtedness and fund investment activity.

At-The-Market Equity Offering Program

On February 19, 2016, the Company entered into sales agreements with five investment banks to allow sales under its at-the-market equity offering program of up to 10,000,000 shares of common stock. A previous sales agreement with one investment bank was terminated effective February 17, 2016.

During the nine months ended September 30, 2016, the Company sold a total of 4,795,601 shares of common stock, including 664,298 shares of common stock under the previous sales agreement. The sales generated \$144.6 million in net proceeds at prices ranging from \$28.31 to \$33.66 per share (weighted average of \$30.61 per share). No shares were sold under this program during the third quarter of 2016.

The Company has 5,868,697 authorized shares remaining available to be sold under the current sales agreements as of October 28, 2016.

Common Stock Dividends

During the nine months ended September 30, 2016, the Company declared and paid common stock dividends totaling \$0.90 per share. On November 1, 2016, the Company declared a quarterly common stock dividend in the amount of \$0.30 per share payable on November 30, 2016 to stockholders of record on November 16, 2016.

Accumulated Other Comprehensive Loss

The following table represents the changes in balances of each component and the amounts reclassified out of accumulated other comprehensive loss related to the Company during the nine months ended September 30, 2016 and 2015:

1	Forward-s Interest R Swaps	C	Benefit Pension Plan
(Dollars in thousands)	2016	2015	20 26 15
Beginning balance	\$(1,569)	\$ —	\$-\$(2,519)
Other comprehensive loss before reclassifications -	_	(1,684)	
Amounts reclassified from accumulated other comprehensive loss arising from loss on defined benefit pension plan		_	-2,519
Amounts reclassified from accumulated other comprehensive loss	126	73	
Net accumulated other comprehensive income (loss)	126	(1,611)	2,519
Ending balance	\$(1,443)	\$(1,611)	\$-\$

13

Dofinad

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

Earnings Per Common Share

The following table sets forth the computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2016 and 2015.

	Three Mo	onths Ended	Nine Months Ended		
	Septembe	er 30,	September 30,		
(Dollars in thousands, except per share data)	2016	2015	2016	2015	
Weighted average Common Shares outstanding					
Weighted average Common Shares outstanding	115,463,2	220 00,440,463	107,829,2	281700,101,187	
Nonvested shares	(1,311,07)	4(1,103,379)	(1,277,45	3(1,107,585)	
Weighted average Common Shares outstanding—Basic	114,152,1	499 ,337,084	106,551,8	398,993,602	
Weighted average Common Shares outstanding—Basic	114,152,1	499 ,337,084	106,551,8	334,993,602	
Dilutive effect of restricted stock	788,265	595,930	697,219	597,713	
Dilutive effect of employee stock purchase plan	111,625	63,541	116,794	102,355	
Weighted average Common Shares outstanding—Dilut	ed15,052,0	39,996,555	107,365,8	3 497 9,693,670	
Net Income (Loss)					
Income from continuing operations	\$11,857	\$ 16,848	\$33,177	\$ 39,482	
Discontinued operations	(23)	10,632	(43)	11,296	
Net income	\$11,834	\$ 27,480	\$33,134	\$ 50,778	
Basic Earnings Per Common Share					
Income from continuing operations	\$0.10	\$ 0.17	\$0.31	\$ 0.40	
Discontinued operations	0.00	0.11	0.00	0.11	
Net income	\$0.10	\$ 0.28	\$0.31	\$ 0.51	
Diluted Earnings Per Common Share					
Income from continuing operations	\$0.10	\$ 0.17	\$0.31	\$ 0.40	
Discontinued operations	0.00	0.10	0.00	0.11	
Net income	\$0.10	\$ 0.27	\$0.31	\$ 0.51	

Incentive Plans

A summary of the activity under the stock-based incentive plans for the three and nine months ended September 30, 2016 and 2015 is included in the table below.

	Three Mon	ths Ended	Nine Months Ended		
	September	30,	September 30,		
	2016 2015		2016	2015	
Stock-based awards, beginning of period	1,311,169	1,103,379	1,092,262	1,057,732	
Granted		520	321,580	112,789	
Vested	(96)	(520)	(102,769)	(67,142)	
Stock-based awards, end of period	1,311,073	1,103,379	1,311,073	1,103,379	

During the nine months ended September 30, 2016 and 2015, the Company withheld 14,442 and 10,119 shares of common stock, respectively, from participants to pay estimated withholding taxes related to shares that vested.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

In addition to the stock-based incentive plans, the Company maintains the 2000 Employee Stock Purchase Plan (the "Purchase Plan"). A summary of the activity under the Purchase Plan for the three and nine months ended September 30, 2016 and 2015 is included in the table below.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2016 2015		2016	2015
Outstanding and exercisable, beginning of period	344,908	365,219	340,958	393,902
Granted			198,450	197,640
Exercised	(13,947)	(3,883)	(51,475)	(39,814)
Forfeited	(3,561)	(9,807)	(17,451)	(41,253)
Expired	_	_	(143,082)	(158,946)
Outstanding and exercisable, end of period	327,400	351,529	327,400	351,529

Note 7. Defined Benefit Pension Plan

Effective May 5, 2015, the Company terminated its Executive Retirement Plan and recorded a charge of approximately \$5.3 million, inclusive of the acceleration of \$2.5 million recorded in accumulated other comprehensive loss on the Company's Condensed Consolidated Balance Sheets that was being amortized resulting in a total benefit obligation of \$19.6 million in connection with the termination of the Executive Retirement Plan. The charge includes amounts resulting from assumed additional years of service for two plan participants who have not reached age 65 and payments associated with FICA and other tax obligations.

On May 6, 2016, the Company paid the total benefit obligation of \$19.6 million, which reduced Other liabilities on the Company's Condensed Consolidated Balance Sheets.

The Company's chairman and chief executive officer, Mr. David Emery, is the only named executive officer that was a participant under the plan. As a result of the termination of the plan, and included in the payment of the total benefit obligation, Mr. Emery received a lump sum amount equal to his accrued benefit under the plan of approximately \$14.4 million in May 2016.

Net periodic benefit cost recorded related to the Company's pension plan for the three and nine months ended September 30, 2016 and 2015 is detailed in the following table.

_	Three		Nine	
	Month	ıs	Months Ended	
	Ended			
	September		September	
	30,		30,	
(Dollars in thousands)	2016	2015	20126015	
Service cost	\$ —	-\$ -	\$ -\$ 29	
Interest cost		_	— 225	
Amortization of net loss		_	— (198)
Amortization of prior service cost		_	— 343	
Total recognized in net periodic benefit cost	\$ —	-\$ -	\$ -\$ 399	

Note 8. Fair Value of Financial Instruments

The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practical to estimate that value.

Cash and cash equivalents - The carrying amount approximates fair value.

Borrowings under the Unsecured Credit Facility and Unsecured Term Loan - The carrying amount approximates fair value because the borrowings are based on variable market interest rates.

Senior unsecured notes payable - The fair value of notes and bonds payable is estimated using cash flow analyses, based on the Company's current interest rates for similar types of borrowing arrangements.

Mortgage notes payable - The fair value is estimated using cash flow analyses, based on the Company's current interest rates for similar types of borrowing arrangements.

Table of Contents

Notes to Condensed Consolidated Financial Statements - Continued

The table below details the fair values and carrying values for notes and bonds payable at September 30, 2016 and December 31, 2015.

September 30, December 31,

2016 2015

(Dollars in millions) Carrying Fair Carrying Fair Value Value Value Value Notes and bonds payable (1) \$1,239.1 \$1,283.9 \$1,425.0 \$1,439.0

⁽¹⁾ Level 3 - Fair value derived from valuation techniques in which one or more significant inputs or significant value drivers is unobservable.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Disclosure Regarding Forward-Looking Statements

This report and other materials the Company has filed or may file with the Securities and Exchange Commission, as well as information included in oral statements or other written statements made, or to be made, by management of the Company, contain, or will contain, disclosures that are "forward-looking statements." Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "target," "intend," "plan," "estimate," "project," "continue," "should," and other comparable terms. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of risks and uncertainties, including the risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, that could significantly affect the Company's current plans and expectations and future financial condition and results.

The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Stockholders and investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in the Company's filings and reports, including, without limitation, estimates and projections regarding the performance of development projects the Company is pursuing.

For a detailed discussion of the Company's risk factors, please refer to the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2015.

The purpose of this Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is to provide an understanding of the Company's consolidated financial condition, results of operations and cash flows by focusing on the changes in certain key measures from year to year. MD&A is provided as a supplement to, and should be read in conjunction with, the Company's Condensed Consolidated Financial Statements and accompanying notes. MD&A is organized in the following sections:

Liquidity and Capital Resources

- Trends and Matters Impacting Operating
- Results

Results of Operations

Liquidity and Capital Resources

Sources and Uses of Cash

The Company's primary sources of cash include rent receipts from its real estate portfolio based on contractual arrangements with its tenants, sponsors and borrowers, borrowings under the Company's Unsecured Credit Facility, proceeds from the sales of real estate properties and proceeds from public or private debt or equity offerings.

The Company expects to continue to meet its liquidity needs, including funding additional investments, paying dividends, and funding debt service through cash on hand, cash flows from operations, and the cash flow sources described above. The Company had unencumbered real estate assets with a gross book value of approximately \$3.3 billion at September 30, 2016, of which a portion could serve as collateral for secured mortgage financing. The Company believes that its liquidity and sources of capital are adequate to satisfy its cash requirements. The Company cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to the Company in sufficient amounts to meet its liquidity needs.

Investing Activities

Cash flows used in investing activities for the nine months ended September 30, 2016 were approximately \$241.0 million. Below is a summary of the significant investing activities.

The Company acquired five medical office buildings during the nine months ended September 30, 2016 for a total purchase price of \$178.2 million, including cash consideration of \$161.1 million, the assumption of mortgage notes payable of \$13.2 million and purchase price adjustments totaling \$3.9 million. Four of these properties are located on hospital campuses and one is adjacent (meaning 0.25 miles or less from the hospital campus) to a hospital campus. The Company funded approximately \$36.2 million at its development and redevelopment properties.

Other items funded during the nine months ended September 30, 2016 include the following:

first generation tenant improvements and planned capital expenditures relating to properties acquired during the most recent two-year period totaling \$11.3 million;

second generation tenant improvements totaling \$15.8 million; and capital expenditures totaling \$12.8 million.

Table of Contents

Subsequent Acquisitions

On October 11, 2016, the Company acquired an 82,763 square foot medical office building and a 30,868 square foot medical office building in Baltimore, Maryland for a total purchase price of \$36.3 million, including purchase price adjustments of \$0.1 million and cash consideration of \$36.4 million. The properties are located on University of Maryland's Upper Chesapeake Health Medical Center campus, a 181-bed acute care hospital. Upon acquisition, the buildings were 92% leased.

On October 17, 2016, the Company acquired a 29,753 square foot medical office building in Seattle, Washington for a purchase price and cash consideration of \$9.8 million. The property is located on Providence Health's Swedish Edmonds campus, a 217-bed acute care hospital. Upon acquisition, the building was 96% leased.

Subsequent Dispositions

On October 14, 2016, the Company disposed of an on-campus, 70,908 square foot medical office building located in Kansas City, Kansas following the ground lessor's exercise of its purchase option. The Company's net investment in the building was \$7.2 million. The sales price and cash proceeds were approximately \$15.1 million. The Company expects to recognize a \$7.6 million gain on the disposal, net of straight-line rent receivables and other assets. This property was classified as held for sale as of September 30, 2016.

On October 28, 2016, the Company disposed of an off-campus, 45,274 square foot medical office building located in Nashville, Tennessee, in which the Company had a net investment of approximately \$6.3 million. The sales price of the building was approximately \$8.8 million, including net proceeds of approximately \$8.6 million and closing costs of approximately \$0.2 million. The Company expects to recognize a \$2.1 million gain on the disposition, net of straight-line rent receivables and other assets. The Company also repaid the related mortgage note payable bearing interest at a rate of 7.63% with outstanding principal of \$0.1 million. This property was classified as held for sale as of September 30, 2016.

Financing Activities

Cash flows provided by financing activities for the nine months ended September 30, 2016 were approximately \$147.1 million. Inflows from accessing the debt and equity markets totaled \$461.8 million, net of issuance costs incurred. Aggregate cash outflows totaled approximately \$314.7 million primarily associated with dividends paid to common stockholders and repayments of indebtedness. See Notes 3, 4 and 6 to the Condensed Consolidated Financial Statements for more information about capital markets and financing activities.

Changes in Debt Structure

On January 5, 2016, the Company obtained a new mortgage note payable of \$11.5 million bearing interest at a rate of 3.60% that encumbers a 90,607 square foot medical office building and garage located in California. The Company repaid in full the previous mortgage note payable bearing an interest rate of 5.49% with outstanding principal of \$11.4 million on December 31, 2015.

On February 11, 2016, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.86% with outstanding principal of \$10.2 million. The mortgage note encumbered a 90,633 square foot medical office building located in North Carolina.

On April 29, 2016, the Company repaid in full a mortgage note payable bearing interest at a rate of 5.99% with outstanding principal of \$7.3 million. The mortgage note encumbered a 42,957 square foot medical office building located in Virginia.

On May 13, 2016, upon acquisition of a 63,012 square foot medical office property in Los Angeles, California, the Company assumed a \$13.2 million mortgage note payable (excluding a fair value premium adjustment of \$0.8 million). The mortgage note payable has a contractual interest rate of 4.77% (effective rate of 4.13%).

With a portion of the proceeds from the equity offering that the Company completed on July 5, 2016, the Company repaid \$50.0 million on its Unsecured Term Loan leaving an outstanding balance of \$150.0 million with a weighted average interest rate of approximately 1.6%.

Table of Contents

On July 29, 2016, the Company entered into an amendment to its Unsecured Credit Facility that extended the maturity date from April 2017 to July 2020, reduced the spread over LIBOR that the Company pays for borrowing, and revised financial covenants to provide the Company with increased flexibility. Amounts outstanding under the Unsecured Credit Facility bear interest at LIBOR plus an applicable margin rate. The margin rate, which depends on the Company's credit ratings, ranges from 0.83% to 1.55% (currently at 1.00%). In addition, the Company pays a facility fee per annum on the aggregate amount of commitments ranging from 0.13% to 0.30% (currently at 0.20%). In connection with the amendment, the Company paid upfront fees to the lenders and other costs of approximately \$4.4 million which will be amortized over the term of the Unsecured Credit Facility. During the third quarter of 2016, the Company had a daily average of \$17.7 million outstanding on the Unsecured Credit Facility. As of September 30, 2016, the Company had \$81.0 million in borrowings outstanding under the Unsecured Credit Facility and had a remaining borrowing capacity of \$619.0 million.

On July 29, 2016, the Company also entered into an amendment to the Unsecured Term Loan. This amendment was for the purpose of conforming the financial covenants in the Unsecured Term Loan to those in the amendment to the Unsecured Credit Facility. The amendment did not impact the maturity date or cost of borrowing under the Unsecured Term Loan.

On September 1, 2016, the Company repaid in full a mortgage note payable bearing interest at a rate of 6.01% with outstanding principal of \$15.7 million. The mortgage note encumbered a 70,623 square foot medical office building located in the state of Washington.

Common Stock Issuances

On February 19, 2016, the Company entered into sales agreements with five investment banks to allow sales under its at-the-market equity offering program of up to 10,000,000 shares of common stock. A previous sales agreement with one investment bank was terminated effective February 17, 2016. During the nine months ended September 30, 2016, the Company sold a total of 4,795,601 shares of common stock, including 664,298 shares of common stock under the previous sales agreement. The sales generated \$144.6 million in net proceeds at prices ranging from \$28.31 to \$33.66 per share (weighted average of \$30.61 per share). No shares were sold under this program during the third quarter of 2016. The Company has 5,868,697 authorized shares remaining available to be sold under the current sales agreements as of October 28, 2016.

On July 5, 2016, the Company issued 9,200,000 shares of common stock, par value \$0.01 per share, at \$33.13 per share in an underwritten public offering pursuant to the Company's existing effective registration statement. The net proceeds of the offering, after offering expenses, were approximately \$304.6 million. A portion of the proceeds were used to repay indebtedness and fund investment activity.

Operating Activities

Cash flows provided by operating activities decreased from \$113.3 million for the nine months ended September 30, 2015 to \$102.4 million for the nine months ended September 30, 2016. This decrease includes the \$19.6 million payment of the pension benefit obligation in connection with the termination of the Executive Retirement Plan. See Note 7 to the Condensed Consolidated Financial Statements for more information. Other items impacting cash flows from operations include, but are not limited to, cash generated from property operations, interest payments and the timing related to the payment of invoices and other expenses and receipts of tenant rent.

The Company may, from time to time, sell additional properties and redeploy cash from property sales and mortgage repayments into new investments. To the extent revenues related to the properties being sold and the mortgages being repaid exceed income from these new investments, the Company's results of operations and cash flows could be adversely affected.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on the Company's financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

New Accounting Pronouncements

See Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report for information on new accounting standards.

Table of Contents

Trends and Matters Impacting Operating Results

Management monitors factors and trends important to the Company and the REIT industry to gauge the potential impact on the operations of the Company. In addition to the matters discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, below are some of the factors and trends that management believes may impact future operations of the Company.

Expiring Leases

The Company expects that approximately 15% to 20% of the leases in its multi-tenanted portfolio will expire each year in the ordinary course of business. There are 447 leases totaling 1.4 million square feet in the Company's multi-tenant portfolio that have expired or will expire during 2016. Approximately 90% of the leases expiring in 2016 are located in buildings on or adjacent to hospital campuses, are distributed throughout the portfolio, and are not concentrated with any one tenant, health system or market area. The Company typically expects to retain 75% to 90% of multi-tenant property tenants upon expiration, and the retention ratio for the first nine months of the year has been within this range.

Two single-tenant net leases expired during the nine months ended September 30, 2016. One tenant entered into a new 11-year lease agreement. The other lease was not renewed, but a new tenant signed a 20-year lease. The Company expects these new lease agreements to result in a decrease in rental income of approximately \$0.5 million in 2016, of which \$0.1 million was realized in the second quarter of 2016, \$0.2 million was realized in the third quarter of 2016 and \$0.2 million is expected to be realized in the fourth quarter of 2016. The Company does not have any other single-tenant net leases that expire by their terms in 2016.

The Company received notice in October 2016 from LifeCare Management Services that it plans to close a 78,731 square foot, long term acute care hospital in Pittsburgh, Pennsylvania that it leases from the Company. The closure is expected to be completed in the fourth quarter of 2016. The single tenant net lease for the facility is scheduled to expire in June 2022, though the Company does not expect to collect rent after October 1, 2016. Assuming no future rental income from the property, the Company expects a quarterly decrease in rental income beginning in the fourth quarter of 2016 of \$0.5 million. The Company is working to sell or lease the property to another health care provider. Property Operating Agreement Expirations

Five of the Company's owned real estate properties as of December 31, 2015 were covered under property operating agreements between the Company and a sponsoring health system. These agreements contractually obligate the sponsoring health system to provide to the Company a minimum return on the Company's investment in the property in exchange for the right to be involved in the operating decisions of the property, including tenancy. If the minimum return is not achieved through normal operations of the property, the Company calculates and accrues to property lease guaranty revenue any shortfalls due from the sponsoring health systems under the terms of the property operating agreement. Of these five agreements, one agreement expired in April 2016, and two more agreements expired on September 30, 2016. As a result of these 2016 expirations, quarterly property lease guaranty revenue was reduced \$0.1 million beginning in April 2016 and a total of \$0.6 million beginning in October 2016. The remaining two agreements will expire in January 2017 and February 2019, respectively, and each is expected to decrease property lease guaranty revenue by \$0.2 million per quarter thereafter.

Operating Expenses

The Company has historically experienced increases in property taxes throughout its portfolio as a result of increasing assessments and tax rates levied across the country. The Company continues its efforts to appeal property tax increases and manage the impact of the increases. In addition, the Company has historically incurred variability in portfolio utilities expense based on seasonality, with the first and third quarters usually reflecting greater amounts. The effects of these operating expense increases are mitigated in leases that have provisions for operating expense reimbursement. As of September 30, 2016, leases for 85% of the Company's multi-tenant leased square footage allow for some recovery of operating expenses, with 54% allowing recovery of all expenses.

Table of Contents

Purchase Options

In July 2016, the Company received notice from the ground lessor of a medical office building in Kansas City, Kansas of its intent to purchase the property pursuant to a purchase option contained in the ground lease. This property was sold in October 2016. The Company's net investment in the building was \$7.2 million at September 30, 2016. The sales price for the building was approximately \$15.1 million and the Company expects to recognize a \$7.6 million gain on the disposal, net of straight-line rent receivables and other assets.

Additional information about the Company's unexercised purchase options and the amount and basis for determination of the purchase price is detailed in the table below (dollars in thousands):

	Gross Real Estate Investment			
	as of September 30, 2016			
	Fair	Non Fair		
	Market	Market		
Year Exercisable	Value	Value	Total	
	Method (1)	Method (2)		
Current	\$128,608	\$	\$128,608	
Remainder of 2016	_	_	_	
2017	_	48,965	48,965	
2018	_	_	_	
2019	41,521	_	41,521	
2020		_	_	
2021	16,578	14,984	31,562	
2022	19,356	_	19,356	
2023		_	_	
2024	16,012	_	16,012	
2025	18,883	221,929	240,812	
2026 and thereafter	92,216		92,216	
Total	\$333,174	\$285,878	\$619,052	

⁽¹⁾ The purchase option price includes a fair market value component that is determined by an appraisal process.

Non-GAAP Financial Measures

Management believes that net income, as defined by GAAP, is the most appropriate earnings measurement. However, management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure historical or future financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable GAAP measure. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of these measures to the most directly comparable GAAP financial measures.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income (determined in accordance with GAAP), as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's

⁽²⁾ Includes properties with stated purchase prices or prices based on fixed capitalization rates. These properties have purchase prices that are on average 13% greater than the Company's current gross investment.

consolidated historical operating results, these measures should be examined in conjunction with net income as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this report.

Funds from Operations

Funds from operations ("FFO") and FFO per share are operating performance measures adopted by the National Association of Real Estate Investment Trusts ("NAREIT"). NAREIT defines FFO as the most commonly accepted and reported measure of a REIT's operating performance equal to "net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus depreciation and amortization related to real estate properties, leasing commission amortization and after adjustments for unconsolidated partnerships and joint ventures." The Company follows the NAREIT definition in calculating and presenting FFO and FFO per share.

Table of Contents

Management believes FFO and FFO per share to be supplemental measures of a REIT's performance because they provide an understanding of the operating performance of the Company's properties without giving effect to certain significant non-cash items, primarily depreciation and amortization expense. Historical cost accounting for real estate assets in accordance with GAAP assumes that the value of real estate assets diminishes predictably over time. However, real estate values instead have historically risen or fallen with market conditions. The Company believes that by excluding the effect of depreciation, amortization and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO and FFO per share can facilitate comparisons of operating performance between periods. The Company reports FFO and FFO per share because these measures are observed by management to also be the predominant measures used by the REIT industry and by industry analysts to evaluate REITs and because FFO per share is consistently reported, discussed, and compared by research analysts in their notes and publications about REITs. For these reasons, management has deemed it appropriate to disclose and discuss FFO and FFO per share. However, FFO does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs. FFO should not be considered as an alternative to net income attributable to common stockholders as an indicator of the Company's operating performance or as an alternative to cash flow from operating activities as a measure of liquidity.

FFO for the three and nine months ended September 30, 2016 compared to the same periods in 2015 was primarily impacted by the various acquisitions and dispositions during the period, the effects of capital market transactions and the results of operations of the portfolio from period to period. FFO for the nine months ended September 30, 2015 was negatively impacted by \$28.0 million, or \$0.28 per common share, as a result of the extinguishment of debt and \$5.3 million, or \$0.05 per common share, as a result of the termination of the Executive Retirement Plan.

The table below reconciles net income to FFO for the three and nine months ended September 30, 2016 and 2015:

		onths eptember	Nine Mont September	
	30,		1	
(Amounts in thousands, except per share data)	2016	2015	2016	2015
Net Income	\$11,834	\$27,480	\$33,134	\$50,778
Gain on sales of properties	_	(16,486)	(8)	(58,035)
Impairments of real estate assets	_	310	_	3,638
Real estate depreciation and amortization	32,557	29,317	95,074	88,076
Total adjustments	32,557	13,141	95,066	33,679
Funds from Operations	\$44,391	\$40,621	\$128,200	\$84,457
Funds from Operations per Common Share—Basic	\$0.39	\$0.41	\$1.20	\$0.85
Funds from Operations per Common Share—Diluted	\$0.39	\$0.41	\$1.19	\$0.85
Weighted Average Common Shares Outstanding—Basic	114,152	99,337	106,552	98,994
Weighted Average Common Shares Outstanding—Dilut	ed15,052	99,997	107,366	98,694

Table of Contents

Same Store Net Operating Income

Net operating income ("NOI") and same store NOI are non-GAAP historical financial measures of performance. Management considers same store NOI a supplemental performance measure because it allows investors, analysts and Company management to measure unlevered property-level operating results. The Company defines NOI as operating revenues (property operating revenue, single-tenant net lease revenue, and property lease guaranty revenue) less property operating expenses related specifically to the property portfolio. NOI excludes straight-line rent, general and administrative expenses, interest expense, depreciation and amortization, gains and losses from property sales, property management fees and other revenues and expenses not specifically related to the property portfolio. Same store NOI is historical and not necessarily indicative of future results.

The following table reflects the Company's same store NOI for the three months ended September 30, 2016 and 2015.

Same Store NOI for the Three Months Ended September 30,

			50,	
		Gross		
(Dollars in thousands)	Number of Properties	Investment		
		at	2016	2015
		September		
		30, 2016		
Multi-tenant Properties	136	\$2,300,520	\$42,572	\$39,577
Single-tenant Net Lease Properties	34	677,171	16,014	16,032
Total	170	\$2,977,691	\$58,586	\$55,609

Properties included in the same store analysis are stabilized properties that have been included in operations and were consistently reported as leased and stabilized properties for the duration of the year-over-year comparison period presented. Accordingly, properties that were recently acquired or disposed of, properties classified as held for sale, and properties in stabilization or conversion from stabilization are excluded from the same store analysis. In addition, the Company excludes properties that meet any of the following Company-defined criteria to be included in the reposition property group:

Properties having less than 60% occupancy that is expected to last at least two quarters;

Properties that experience a loss of occupancy over 30% in a single quarter;

Properties with negative net operating income that is expected to last at least two quarters; or

Condemnation.

Any recently acquired property will be included in the same store pool once the Company has owned the property for eight full quarters. Development properties will be included in the same store pool eight full quarters after substantial completion. Any property included in the reposition property group will be included in the same store analysis once occupancy has increased to 60% or greater with positive net operating income and has remained at that level for eight full quarters.

Table of Contents

The following tables reconcile net income to same store NOI and the same store property count to the total owned real estate portfolio:

Reconciliation of Same Store NOI:

	Three Mo	onths
	Ended Se	ptember
	30,	
(Dollars in thousands)	2016	2015
Net income	\$11,834	\$27,480
Loss (income) from discontinued operations	23	(10,632)
Income from continuing operations	11,857	16,848
General and administrative	8,724	6,258
Depreciation	29,273	26,571
Amortization	2,712	2,386
Bad debts, net of recoveries	(47)	(21)
Gain on sales of real estate properties	_	(5,915)
Interest expense	13,759	15,113
Impairment of real estate assets	_	310
Interest and other income, net	(123)	(72)
Mortgage interest	_	(29)
Straight-line rent (component of Rental income)	(1,223)	(2,309)
Other operating (a)	(308)	(314)
NOI	64,624	58,826
NOI not included in same store	(6,038)	(3,217)
Same store NOI	\$58,586	\$55,609
(a) Other operating income reconciliation		
Other operating	\$1,125	\$1,313
Less: Rental lease guaranty income	(817)	(999)
	\$308	\$314

Reconciliation of Same Store Property Count:

Property
Count as of
September
30, 2016

Same Store Properties
170

Acquisitions
15

Development Conversion
1

Reposition
16

Total Owned Real Estate Properties
202

Table of Contents

Results of Operations

Three Months Ended September 30, 2016 Compared to Three Months Ended September 30, 2015

The Company's results of operations for the three months ended September 30, 2016 compared to the same period in 2015 were significantly impacted by acquisitions, dispositions, gains, impairments recorded and capital markets transactions.

Revenues

Rental income increased \$7.2 million, or 7.5%, to approximately \$102.5 million for the three months ended September 30, 2016 compared to \$95.4 million in the prior year period and is comprised of the following:

Three Months
Ended September Change

30,

(Dollars in thousands) 2016 2015 \$ %
Property operating \$85,264 \$76,960 \$8,304 10.8 %
Single-tenant net lease 16,047 16,114 (67) (0.4)%
Straight-line rent 1,223 2,309 (1,086) (47.0)%
Total rental income \$102,534 \$95,383 \$7,151 7.5 %

Property operating income increased \$8.3 million, or 10.8%, from the prior year period primarily as a result of the following activity:

Acquisitions in 2015 and 2016 contributed \$4.8 million.

Leasing activity including contractual rent increases contributed \$4.2 million.

Dispositions in 2015 caused a decrease of \$0.7 million

Single-tenant net lease revenue decreased \$0.1 million, or 0.4%, from the prior year period primarily as a result of the following activity:

Dispositions in 2015 caused a decrease of \$0.1 million.

Reduction in lease revenue of \$0.2 million upon expiration and execution of new leases (see "Management's

Discussion and Analysis of Financial Condition and Results of Operations - Trends and Matters Impacting Operating Results" for additional information).

Contractual rent increases contributed \$0.2 million.

Straight-line rent decreased \$1.1 million, or 47.0%, from the prior year period primarily as a result of the following activity:

Net leasing activity including contractual rent increases and the effects of prior year rent abatements that expired resulted in a decrease of \$1.3 million.

Acquisitions in 2015 and 2016 caused an increase of \$0.2 million.

Expenses

Property operating expenses increased \$2.3 million, or 6.4%, for the three months ended September 30, 2016 compared to the prior year period primarily as a result of the following activity:

Acquisitions in 2015 and 2016 caused an increase of \$1.9 million.

Increases in portfolio property tax of approximately \$0.7 million and compensation-related expenses of approximately \$0.3 million.

Dispositions in 2015 caused a decrease of \$0.6 million.

General and administrative expenses increased approximately \$2.5 million, or 39.4%, for the three months ended September 30, 2016 compared to the prior year period primarily as a result of the following activity:

Increase in performance-based compensation expense of \$1.5 million.

Increase in payroll compensation of \$0.2 million.

Table of Contents

Increase in expenses related to actual and potential acquisitions and developments of \$0.5 million.

• Increase in professional fees and other administrative costs of \$0.3 million.

Depreciation expense increased \$2.7 million, or 10.2%, for the three months ended September 30, 2016 compared to the prior year period primarily as a result of the following activity:

- Acquisitions in 2015 and 2016 caused an increase of \$1.6 million.
- Various building and tenant improvement expenditures caused an increase of \$1.8 million.
- Dispositions in 2015 caused a decrease of \$0.4 million.
- Assets that became fully depreciated resulted in a decrease of \$0.3 million.

Other income (expense)

In 2015, the Company recorded gains of approximately \$5.9 million on the sale of two properties and an impairment charge of approximately \$0.3 million on the sale of one property. There were no such transactions in 2016. Interest expense decreased \$1.4 million for the three months ended September 30, 2016 compared to the prior year period. The components of interest expense are as follows:

	Three Mo	nths			
	Ended September		Change		
	30,				
(Dollars in thousands)	2016	2015	\$	%	
Contractual interest	\$13,379	\$14,445	\$(1,066)	(7.4)%
Net discount/premium accretion	(33)	(28)	(5)	17.9	%
Deferred financing costs amortization	748	734	14	1.9	%
Interest rate swap amortization	42	42		_	%
Interest cost capitalization	(377)	(80)	(297)	371.3	%
Total interest expense	\$13,759	\$15,113	\$(1,354)	(9.0))%

Contractual interest expense decreased \$1.1 million primarily due to the following activity:

The Company repaid the outstanding balance on the Unsecured Credit Facility on July 5, 2016, resulting in a decrease in interest expense of approximately \$0.7 million. The Company borrowings on the Unsecured Credit Facility during the quarter averaged \$17.7 million outstanding.

Mortgage notes payable repayments resulted in a decrease in interest expense of approximately \$0.2 million.

The Company repaid \$50.0 million on the outstanding balance of the Unsecured Term Loan, resulting in a decrease in interest expense of approximately \$0.2 million.

Discontinued Operations

Results from discontinued operations for the three months ended September 30, 2015 included a gain on sale of \$10.6 million related to one property classified as held for sale at December 31, 2014 that was subsequently sold.

Table of Contents

Results of Operations

Nine Months Ended September 30, 2016 Compared to Nine Months Ended September 30, 2015

The Company's results of operations for the nine months ended September 30, 2016 compared to the same period in 2015 were significantly impacted by acquisitions, dispositions, gains, impairments recorded and capital markets transactions.

Revenues

Rental income increased \$16.9 million, or 5.9%, to approximately \$302.7 million for the nine months ended September 30, 2016 compared to \$285.9 million in the prior year period and is comprised of the following:

Nine Mon September	ths Ended r 30,	Change	•	•
2016	2015	\$	%	
\$249,049	\$227,084	\$21,965	9.7	%
48,251	51,167	(2,916)	(5.7)%
5,446	7,616	(2,170)	(28.5)%
\$302,746	\$285,867	\$16,879	5.9	%
	2016 \$249,049 48,251 5,446	2016 2015 \$249,049 \$227,084 48,251 51,167 5,446 7,616	2016 2015 \$ \$249,049 \$227,084 \$21,965 48,251 51,167 (2,916) 5,446 7,616 (2,170)	2016 2015 \$ % \$249,049 \$227,084 \$21,965 9.7 48,251 51,167 (2,916) (5.7

Property operating income increased \$22.0 million, or 9.7%, from the prior year period primarily as a result of the following activity:

Acquisitions in 2015 and 2016 contributed \$13.0 million.

Leasing activity including contractual rent increases contributed \$11.2 million.

Dispositions in 2015 caused a decrease of \$2.2 million.

Single-tenant net lease revenue decreased \$2.9 million, or 5.7%, from the prior year period primarily as a result of the following activity:

Dispositions in 2015 caused a decrease of \$3.2 million.

Reduction in lease revenue of \$0.3 million upon expiration and execution of new leases (see "Management's

Discussion and Analysis of Financial Condition and Results of Operations - Trends and Matters Impacting Operating Results" for additional information).

Leasing activity including contractual rent increases contributed \$0.6 million.

Straight-line rent decreased \$2.2 million, or 28.5%, from the prior year period primarily as a result of the following activity:

Net leasing activity including contractual rent increases and the effects of prior year rent abatements that expired resulted in a decrease of \$2.7 million.

Dispositions in 2015 caused a decrease of \$0.3 million.

Acquisitions in 2015 and 2016 caused an increase of \$0.8 million.

Expenses

Property operating expenses increased \$5.7 million, or 5.5%, for the nine months ended September 30, 2016 compared to the prior year period primarily as a result of the following activity:

Acquisitions in 2015 and 2016 caused an increase of \$5.3 million.

Increase of \$3.3 million from the following operating expense categories: portfolio property tax of approximately \$1.8 million;

leasing commission amortization of \$0.5 million;

compensation-related expenses of approximately \$0.5 million; administrative and legal cost of \$0.3 million; and portfolio maintenance repair expense of approximately \$0.2 million.

Table of Contents

Decrease in portfolio utilities of approximately \$0.9 million.

Dispositions in 2015 caused a decrease of \$2.0 million.

General and administrative expenses increased approximately \$7.4 million, or 37.5%, for the nine months ended September 30, 2016 compared to the prior year period primarily as a result of the following activity:

Increase in performance-based compensation expense of \$3.9 million.

Increase in payroll expense of \$0.7 million.

Increase in expenses related to actual and potential acquisitions and developments of \$2.4 million.

Other net increases, including telecommunication expense of \$0.4 million.

Depreciation expense increased \$6.0 million, or 7.5%, for the nine months ended September 30, 2016 compared to the prior year period primarily as a result of the following activity:

Acquisitions in 2015 and 2016 caused an increase of \$4.1 million.

Various building and tenant improvement expenditures caused an increase of \$4.8 million.

Dispositions in 2015 caused a decrease of \$2.2 million.

Assets that became fully depreciated resulted in a decrease of \$0.7 million.

Other income (expense)

In 2015, the Company recorded gains of approximately \$47.5 million on the sale of five properties and an impairment charge of approximately \$0.3 million on the sale of one property. There were no such transactions in 2016.

In 2015, the Company recorded an impairment charge of \$3.3 million on a property that was reclassified to held for sale, due to management's decision to sell, to adjust the carrying value to fair value less estimated costs to sell which was subsequently sold.

Interest expense decreased \$7.1 million for the nine months ended September 30, 2016 compared to the prior year period. The components of interest expense are as follows:

	Nine Mor	ıths		
	Ended September		Change	
	30,			
(Dollars in thousands)	2016	2015	\$	%
Contractual interest	\$42,097	\$47,938	\$(5,841)	(12.2)%
Net discount/premium accretion	(93)	426	(519)	(121.8)%
Deferred financing costs amortization	2,210	2,325	(115)	(4.9)%
Interest rate swap amortization	126	73	53	72.6 %
Interest cost capitalization	(828)	(113)	(715)	632.7 %
Total interest expense	\$43,512	\$50,649	\$(7,137)	(14.1)%

Contractual interest expense decreased \$5.8 million primarily due to the following activity:

The redemption of the Unsecured Senior Notes due 2017 completed in May 2015 resulted in a decrease in interest expense of approximately \$7.2 million.

Mortgage notes payable repayments resulted in a decrease in interest expense of approximately \$0.9 million.

The issuance of the Unsecured Senior Notes due 2025 in April 2015 caused an increase in interest expense of approximately \$3.0 million.

Reduced borrowings under the Unsecured Credit Facility and the Unsecured Term Loan resulted in a decrease in interest expense of approximately \$0.7 million.

Loss on extinguishment of debt of approximately \$28.0 million is associated with the 2015 redemption of the Unsecured Senior Notes due 2017.

Table of Contents

Pension termination of approximately \$5.3 million represents the effect of the Company's termination of the Executive Retirement Plan in 2015. See Note 7 to the Condensed Consolidated Financial Statements for more information. The Company recognized an impairment of internally-developed software of approximately \$0.7 million in 2015, which was abandoned for a third party program that was previously unavailable.

Discontinued Operations

Results from discontinued operations for the nine months ended September 30, 2015 included income of \$11.3 million primarily related to the gain on sale of one property classified as held for sale at December 31, 2014 that was subsequently sold.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

The Company is exposed to market risk in the form of changing interest rates on its debt and mortgage notes and other notes receivable. Management uses regular monitoring of market conditions and analysis techniques to manage this risk. During the nine months ended September 30, 2016, there were no material changes in the quantitative and qualitative disclosures about market risks presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2015.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on this evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures were effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports it files or submits under the Exchange Act. Changes in Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

The Company is, from time to time, involved in litigation arising in the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.

Item 1A. Risk Factors

In addition to the other information set forth in this report, an investor should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect the Company's business, financial condition or future results. The risks, as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, are not the only risks facing the Company. Additional risks and uncertainties not currently known to management or that management currently deems immaterial also may materially, adversely affect the Company's business, financial condition, operating results or cash flows.

Table of Contents

Item 6. Exhibit Exhibit Exhibit 3.1	ts Description Second Articles of Amendment and Restatement of the Company, as amended ⁽¹⁾
Exhibit 3.2	Amended and Restated Bylaws of the Company, as amended ⁽¹⁾
Exhibit 4.1	Specimen Stock Certificate ⁽²⁾
Exhibit 4.2	Indenture, dated as of May 15, 2001, by and between the Company and Regions Bank, as trustee ⁽³⁾
Exhibit 4.3	Fourth Supplemental Indenture, dated December 13, 2010, by and between the Company and Regions Bank, as $Trustee^{(4)}$
Exhibit 4.4	Form of 5.750% Senior Notes due 2021 (set forth in Exhibit B to the Fourth Supplemental Indenture filed as Exhibit 4.5 thereto) ⁽⁴⁾
Exhibit 4.5	Fifth Supplemental Indenture, dated March 26, 2013, by and between the Company and Regions Bank, as Trustee ⁽⁵⁾
Exhibit 4.6	Form of 3.75% Senior Notes due 2023 (set forth in Exhibit B to the Fifth Supplemental Indenture filed as Exhibit 4.7 thereto) ⁽⁵⁾
Exhibit 4.7	Sixth Supplemental Indenture, dated April 24, 2015, by and between the Company and Regions Bank, as $Trustee^{(6)}$
Exhibit 4.8	Form of 3.875% Senior Notes due 2025 (set forth in Exhibit B to the Sixth Supplemental Indenture filed as Exhibit 4.9 thereto) ⁽⁶⁾
Exhibit 10.1	Third Amendment to Credit Agreement, dated as of July 29, 2016, by and among the Company, as Borrower, Wells Fargo Bank National Association, as Administrative Agent, and the other lenders that are party thereto. (7)
Exhibit 10.2	First Amendment to Term Loan Agreement, dated as of July 29, 2016, by and among the Company, as Borrower, Wells Fargo Bank National Association, as Administrative Agent, and the other lenders that are party thereto. (7)
Exhibit 11	Statement re: Computation of per share earnings (filed herewith in Note 6 to the Condensed Consolidated Financial Statements)
Exhibit 31.1	Certification of the Chief Executive Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Exhibit 31.2	Certification of the Chief Financial Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the

Exhibit 32	Sarbanes-Oxley Act of 2002 (furnished herewith)
Exhibit 101.INS	XBRL Instance Document (filed herewith)
Exhibit 101.SCH	XBRL Taxonomy Extension Schema Document (filed herewith)
Exhibit	XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)

Exhibit 101.LAB XBRL Taxonomy Extension Labels Linkbase Document (filed herewith)

Exhibit 101.DEF XBRL Taxonomy Extension Definition Linkbase Document (filed herewith)

Exhibit 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)

31

101.CAL

⁽¹⁾ Filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2015 and hereby incorporated by reference.

⁽²⁾ Filed as an exhibit to the Company's Registration Statement on Form S-11 (Registration No. 33-60506) previously filed pursuant to the Securities Act of 1933 and hereby incorporated by reference.

⁽³⁾ Filed as an exhibit to the Company's Form 8-K filed May 17, 2001 and hereby incorporated as reference.

⁽⁴⁾ Filed as an exhibit to the Company's Form 8-K filed December 13, 2010 and hereby incorporated by reference.

⁽⁵⁾ Filed as an exhibit to the Company's Form 8-K filed March 26, 2013 and hereby incorporated by reference.

⁽⁶⁾ Filed as an exhibit to the Company's Form 8-K filed April 24, 2015 and hereby incorporated by reference.

Filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2016 and hereby incorporated by reference.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HEALTHCARE REALTY TRUST INCORPORATED

By:/s/ J. CHRISTOPHER DOUGLAS

J. Christopher Douglas

Executive Vice President and Chief Financial Officer

Date: November 2, 2016

Table of Contents

Exhibit Index Exhibit Exhibit 3.1	Description Second Articles of Amendment and Restatement of the Company, as amended ⁽¹⁾
Exhibit 3.2	Amended and Restated Bylaws of the Company, as amended ⁽¹⁾
Exhibit 4.1	Specimen Stock Certificate ⁽²⁾
Exhibit 4.2	Indenture, dated as of May 15, 2001, by and between the Company and Regions Bank, as trustee ⁽³⁾
Exhibit 4.3	Fourth Supplemental Indenture, dated December 13, 2010, by and between the Company and Regions Bank, as Trustee ⁽⁴⁾
Exhibit 4.4	Form of 5.750% Senior Notes due 2021 (set forth in Exhibit B to the Fourth Supplemental Indenture filed as Exhibit 4.5 thereto) ⁽⁴⁾
Exhibit 4.5	Fifth Supplemental Indenture, dated March 26, 2013, by and between the Company and Regions Bank, as Trustee ⁽⁵⁾
Exhibit 4.6	Form of 3.75% Senior Notes due 2023 (set forth in Exhibit B to the Fifth Supplemental Indenture filed as Exhibit 4.7 thereto) ⁽⁵⁾
Exhibit 4.7	Sixth Supplemental Indenture, dated April 24, 2015, by and between the Company and Regions Bank, as Trustee ⁽⁶⁾
Exhibit 4.8	Form of 3.875% Senior Notes due 2025 (set forth in Exhibit B to the Sixth Supplemental Indenture filed as Exhibit 4.9 thereto) ⁽⁶⁾
Exhibit 10.1	Third Amendment to Credit Agreement, dated as of July 29, 2016, by and among the Company, as Borrower, Wells Fargo Bank National Association, as Administrative Agent, and the other lenders that are party thereto. (7)
Exhibit 10.2	First Amendment to Term Loan Agreement, dated as of July 29, 2016, by and among the Company, as Borrower, Wells Fargo Bank National Association, as Administrative Agent, and the other lenders that are party thereto. (7)
Exhibit 11	Statement re: Computation of per share earnings (filed herewith in Note 6 to the Condensed Consolidated Financial Statements)
Exhibit 31.1	Certification of the Chief Executive Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Exhibit 31.2	Certification of the Chief Financial Officer of Healthcare Realty Trust Incorporated pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)

Exhibit 101.INS XBRL Instance Document (filed herewith)

Exhibit 101.SCH XBRL Taxonomy Extension Schema Document (filed herewith)

Exhibit 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)

Exhibit 101.LAB XBRL Taxonomy Extension Labels Linkbase Document (filed herewith)

Exhibit 101.DEF XBRL Taxonomy Extension Definition Linkbase Document (filed herewith)

Exhibit 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)

⁽¹⁾ Filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2015 and hereby incorporated by reference.

⁽²⁾ Filed as an exhibit to the Company's Registration Statement on Form S-11 (Registration No. 33-60506) previously filed pursuant to the Securities Act of 1933 and hereby incorporated by reference.

⁽³⁾ Filed as an exhibit to the Company's Form 8-K filed May 17, 2001 and hereby incorporated as reference.

⁽⁴⁾ Filed as an exhibit to the Company's Form 8-K filed December 13, 2010 and hereby incorporated by reference.

⁽⁵⁾ Filed as an exhibit to the Company's Form 8-K filed March 26, 2013 and hereby incorporated by reference.

⁽⁶⁾ Filed as an exhibit to the Company's Form 8-K filed April 24, 2015 and hereby incorporated by reference.

Filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2016 and hereby incorporated by reference.